565 related articles for article (PubMed ID: 25726868)
1. Cancer immunotherapy using novel tumor-associated antigenic peptides identified by genome-wide cDNA microarray analyses.
Nishimura Y; Tomita Y; Yuno A; Yoshitake Y; Shinohara M
Cancer Sci; 2015 May; 106(5):505-11. PubMed ID: 25726868
[TBL] [Abstract][Full Text] [Related]
2. Identification of promiscuous KIF20A long peptides bearing both CD4+ and CD8+ T-cell epitopes: KIF20A-specific CD4+ T-cell immunity in patients with malignant tumor.
Tomita Y; Yuno A; Tsukamoto H; Senju S; Kuroda Y; Hirayama M; Irie A; Kawahara K; Yatsuda J; Hamada A; Jono H; Yoshida K; Tsunoda T; Kohrogi H; Yoshitake Y; Nakamura Y; Shinohara M; Nishimura Y
Clin Cancer Res; 2013 Aug; 19(16):4508-20. PubMed ID: 23714729
[TBL] [Abstract][Full Text] [Related]
3. Identification of CDCA1-derived long peptides bearing both CD4+ and CD8+ T-cell epitopes: CDCA1-specific CD4+ T-cell immunity in cancer patients.
Tomita Y; Yuno A; Tsukamoto H; Senju S; Yoshimura S; Osawa R; Kuroda Y; Hirayama M; Irie A; Hamada A; Jono H; Yoshida K; Tsunoda T; Kohrogi H; Yoshitake Y; Nakamura Y; Shinohara M; Nishimura Y
Int J Cancer; 2014 Jan; 134(2):352-66. PubMed ID: 24734272
[TBL] [Abstract][Full Text] [Related]
4. Identification of a novel tumor-associated antigen, cadherin 3/P-cadherin, as a possible target for immunotherapy of pancreatic, gastric, and colorectal cancers.
Imai K; Hirata S; Irie A; Senju S; Ikuta Y; Yokomine K; Harao M; Inoue M; Tsunoda T; Nakatsuru S; Nakagawa H; Nakamura Y; Baba H; Nishimura Y
Clin Cancer Res; 2008 Oct; 14(20):6487-95. PubMed ID: 18927288
[TBL] [Abstract][Full Text] [Related]
5. HLA-A2-restricted CTL epitopes of a novel lung cancer-associated cancer testis antigen, cell division cycle associated 1, can induce tumor-reactive CTL.
Harao M; Hirata S; Irie A; Senju S; Nakatsura T; Komori H; Ikuta Y; Yokomine K; Imai K; Inoue M; Harada K; Mori T; Tsunoda T; Nakatsuru S; Daigo Y; Nomori H; Nakamura Y; Baba H; Nishimura Y
Int J Cancer; 2008 Dec; 123(11):2616-25. PubMed ID: 18770861
[TBL] [Abstract][Full Text] [Related]
6. A novel tumor-associated antigen, cell division cycle 45-like can induce cytotoxic T-lymphocytes reactive to tumor cells.
Tomita Y; Imai K; Senju S; Irie A; Inoue M; Hayashida Y; Shiraishi K; Mori T; Daigo Y; Tsunoda T; Ito T; Nomori H; Nakamura Y; Kohrogi H; Nishimura Y
Cancer Sci; 2011 Apr; 102(4):697-705. PubMed ID: 21231984
[TBL] [Abstract][Full Text] [Related]
7. Ring finger protein 43 as a new target for cancer immunotherapy.
Uchida N; Tsunoda T; Wada S; Furukawa Y; Nakamura Y; Tahara H
Clin Cancer Res; 2004 Dec; 10(24):8577-86. PubMed ID: 15623641
[TBL] [Abstract][Full Text] [Related]
8. EGFR inhibitors augment antitumour helper T-cell responses of HER family-specific immunotherapy.
Kumai T; Matsuda Y; Oikawa K; Aoki N; Kimura S; Harabuchi Y; Celis E; Kobayashi H
Br J Cancer; 2013 Oct; 109(8):2155-66. PubMed ID: 24045666
[TBL] [Abstract][Full Text] [Related]
9. An oncofetal antigen, IMP-3-derived long peptides induce immune responses of both helper T cells and CTLs.
Hirayama M; Tomita Y; Yuno A; Tsukamoto H; Senju S; Imamura Y; Sayem MA; Irie A; Yoshitake Y; Fukuma D; Shinohara M; Hamada A; Jono H; Yuba E; Kono K; Yoshida K; Tsunoda T; Nakayama H; Nishimura Y
Oncoimmunology; 2016 Jun; 5(6):e1123368. PubMed ID: 27471607
[TBL] [Abstract][Full Text] [Related]
10. p53 as an immunotherapeutic target in head and neck cancer.
Hoffmann TK; Bier H; Donnenberg AD; Whiteside TL; De Leo AB
Adv Otorhinolaryngol; 2005; 62():151-60. PubMed ID: 15608425
[TBL] [Abstract][Full Text] [Related]
11. Bladder cancer-associated cancer-testis antigen-derived long peptides encompassing both CTL and promiscuous HLA class II-restricted Th cell epitopes induced CD4
Tsuruta M; Ueda S; Yew PY; Fukuda I; Yoshimura S; Kishi H; Hamana H; Hirayama M; Yatsuda J; Irie A; Senju S; Yuba E; Kamba T; Eto M; Nakayama H; Nishimura Y
Oncoimmunology; 2018; 7(4):e1415687. PubMed ID: 29632734
[TBL] [Abstract][Full Text] [Related]
12. Comparative analysis of various tumor-associated antigen-specific t-cell responses in patients with hepatocellular carcinoma.
Mizukoshi E; Nakamoto Y; Arai K; Yamashita T; Sakai A; Sakai Y; Kagaya T; Yamashita T; Honda M; Kaneko S
Hepatology; 2011 Apr; 53(4):1206-16. PubMed ID: 21480325
[TBL] [Abstract][Full Text] [Related]
13. Identification of HLA-A2-restricted CTL epitopes of a novel tumour-associated antigen, KIF20A, overexpressed in pancreatic cancer.
Imai K; Hirata S; Irie A; Senju S; Ikuta Y; Yokomine K; Harao M; Inoue M; Tomita Y; Tsunoda T; Nakagawa H; Nakamura Y; Baba H; Nishimura Y
Br J Cancer; 2011 Jan; 104(2):300-7. PubMed ID: 21179034
[TBL] [Abstract][Full Text] [Related]
14. A wild-type sequence p53 peptide presented by HLA-A24 induces cytotoxic T lymphocytes that recognize squamous cell carcinomas of the head and neck.
Eura M; Chikamatsu K; Katsura F; Obata A; Sobao Y; Takiguchi M; Song Y; Appella E; Whiteside TL; DeLeo AB
Clin Cancer Res; 2000 Mar; 6(3):979-86. PubMed ID: 10741724
[TBL] [Abstract][Full Text] [Related]
15. Identification of a gene coding for a protein possessing shared tumor epitopes capable of inducing HLA-A24-restricted cytotoxic T lymphocytes in cancer patients.
Yang D; Nakao M; Shichijo S; Sasatomi T; Takasu H; Matsumoto H; Mori K; Hayashi A; Yamana H; Shirouzu K; Itoh K
Cancer Res; 1999 Aug; 59(16):4056-63. PubMed ID: 10463607
[TBL] [Abstract][Full Text] [Related]
16. Identification of secernin 1 as a novel immunotherapy target for gastric cancer using the expression profiles of cDNA microarray.
Suda T; Tsunoda T; Uchida N; Watanabe T; Hasegawa S; Satoh S; Ohgi S; Furukawa Y; Nakamura Y; Tahara H
Cancer Sci; 2006 May; 97(5):411-9. PubMed ID: 16630140
[TBL] [Abstract][Full Text] [Related]
17. Screening of HLA-A24-restricted epitope peptides from prostate-specific membrane antigen that induce specific antitumor cytotoxic T lymphocytes.
Horiguchi Y; Nukaya I; Okazawa K; Kawashima I; Fikes J; Sette A; Tachibana M; Takesako K; Murai M
Clin Cancer Res; 2002 Dec; 8(12):3885-92. PubMed ID: 12473604
[TBL] [Abstract][Full Text] [Related]
18. PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma.
Hirata-Nozaki Y; Ohkuri T; Ohara K; Kumai T; Nagata M; Harabuchi S; Kosaka A; Nagato T; Ishibashi K; Oikawa K; Aoki N; Ohara M; Harabuchi Y; Uno Y; Takei H; Celis E; Kobayashi H
J Transl Med; 2019 Jun; 17(1):207. PubMed ID: 31221178
[TBL] [Abstract][Full Text] [Related]
19. Unraveling the role of preexisting immunity in prostate cancer patients vaccinated with a HER-2/neu hybrid peptide.
Voutsas IF; Anastasopoulou EA; Tzonis P; Papamichail M; Perez SA; Baxevanis CN
J Immunother Cancer; 2016; 4():75. PubMed ID: 27891225
[TBL] [Abstract][Full Text] [Related]
20. Identification of SPARC as a candidate target antigen for immunotherapy of various cancers.
Inoue M; Senju S; Hirata S; Ikuta Y; Hayashida Y; Irie A; Harao M; Imai K; Tomita Y; Tsunoda T; Furukawa Y; Ito T; Nakamura Y; Baba H; Nishimura Y
Int J Cancer; 2010 Sep; 127(6):1393-403. PubMed ID: 20063317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
